Reflux Esophagitis (Gastroesophageal Reflux Disease) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Reflux Esophagitis (Gastroesophageal Reflux Disease) – Pipeline Review, H2 2017’, provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease)

The report reviews pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Reflux Esophagitis (Gastroesophageal Reflux Disease) therapeutics and enlists all their major and minor projects

The report assesses Reflux Esophagitis (Gastroesophageal Reflux Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ahn-Gook Pharmaceutical Co Ltd

Cempra Inc

Daewoong Pharmaceutical Co Ltd

Eisai Co Ltd

Ilyang Pharmaceutical Co Ltd

Ironwood Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

RaQualia Pharma Inc

Takeda Pharmaceutical Company Ltd

Wockhardt Ltd

Yooyoung Pharm Co Ltd

Yuyu Pharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Overview

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Companies Involved in Therapeutics Development

Ahn-Gook Pharmaceutical Co Ltd

Cempra Inc

Daewoong Pharmaceutical Co Ltd

Eisai Co Ltd

Ilyang Pharmaceutical Co Ltd

Ironwood Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

RaQualia Pharma Inc

Takeda Pharmaceutical Company Ltd

Wockhardt Ltd

Yooyoung Pharm Co Ltd

Yuyu Pharma Inc

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Drug Profiles

(lansoprazole + omeprazole) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ceclazepide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CEM-031 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexlansoprazole DR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWJ-1367 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWP-14012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-3710 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-17DT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ilaprazole DR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IW-3718 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JP-1366 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naronapride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

netazepide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pantoprazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00000774 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Potassium Transporting ATPase Alpha Chain 1 Inhibitor for Peptic Ulcers and Reflux Esophagitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Tubulin for Barrett's Esophageal Adenocarcinoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tegoprazan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tenatoprazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YY-DXR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YYD-601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Product Development Milestones

Featured News & Press Releases

Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-3718 at R&D Day 2017

Nov 16, 2016: Renexxion Achieves Positive FDA Guidance for Phase 3-ready GI Drug Naronapride

Jul 11, 2016: Takeda Announces FDA Approval of Dexilant (dexlansoprazole) for Patients 12-17 Years of Age

Mar 23, 2016: Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial of IW-3718 in Refractory Gastroesophageal Reflux Disease

Feb 18, 2016: RaQualia Receives a Patent Allowance for Acid Pump Antagonist in Korea

Jan 27, 2016: FDA Approves Takeda’s Dexilant SoluTab (dexlansoprazole)

Oct 19, 2015: Ironwood Highlights Refractory GERD Research at the American College of Gastroenterology 2015 Annual Scientific Meeting

Feb 04, 2015: Ironwood Reports Positive Top-Line Data from Exploratory Phase IIa Trial Of IW-3718 in Refractory Gastroesophageal Reflux Disease

Mar 18, 2014: Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-3718 in Refractory Gastroesophageal Reflux Disease

Dec 19, 2013: Dexlansoprazole, a New Dual-Delayed Release Technology for the Treatment Of Reflux Disease, Accepted for National Approvals Within the European Union

Dec 19, 2013: Dexlansoprazole, a New Dual-Delayed Release Technology for the Treatment Of Reflux Disease, Accepted for National Approvals Within the European Union

Oct 15, 2013: TWi Pharmaceuticals Comments on Dexilant Ruling

Sep 04, 2012: Santarus Announces Appellate Court Reversal In Part Of Zegerid Invalidity Decision

Nov 17, 2011: Takeda Provides Update On DEXILANT Product Labeling

Jul 27, 2011: Ilyang Pharmaceuticals Obtains Patent For Ilaprazole

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Pipeline by Ahn-Gook Pharmaceutical Co Ltd, H2 2017

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Pipeline by Cempra Inc, H2 2017

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Pipeline by Eisai Co Ltd, H2 2017

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Pipeline by Ilyang Pharmaceutical Co Ltd, H2 2017

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Pipeline by Ironwood Pharmaceuticals Inc, H2 2017

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Pipeline by RaQualia Pharma Inc, H2 2017

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Pipeline by Wockhardt Ltd, H2 2017

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Pipeline by Yooyoung Pharm Co Ltd, H2 2017

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Pipeline by Yuyu Pharma Inc, H2 2017

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Dormant Projects, H2 2017

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Dormant Projects, H2 2017 (Contd..1), H2 2017

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Dormant Projects, H2 2017 (Contd..2), H2 2017

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Discontinued Products, H2 2017

Reflux Esophagitis (Gastroesophageal Reflux Disease) – Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

List of Figures

Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports